UNSPSC 51341702: Xenygloxal

This classification denotes an antiviral agent and antimicrobial with the molecular formula C16H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3C2T3HG40E, chemically known as 4,4-diphenyldicarboxaldehyde but generally known as xenygloxal, which bears US NIH Compound Identifier 239061. European Medicines Agency schedules Xenygloxal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00106MIG.

UNSPSC 51341702 Xenygloxal, a Commodity code, shows state and local governments soliciting pharmaceutical products and drug-related medical supplies, though recent activity reflects naloxone procurement, direct-to-manufacturer pharmacy initiatives, and generic pharmaceutical sourcing rather than the abstract code name alone. Issuing bodies span county health departments, state health and human services commissions, municipal fire departments, and multistate cooperative purchasing alliances. Work ranges from emergency naloxone and safe drug deactivation system procurement to medical and first aid supplies for rescue operations, generic pharmaceutical contracting through authorized wholesalers, and pharmacy benefit program modernization. Seminole County, Florida; the City of Tampa; the Texas Health and Human Services Commission; and the Minnesota Department of Administration (via MMCAP) represent the issuing-body mix, with MMCAP operating a multistate cooperative vehicle serving state and local government facilities across multiple jurisdictions including Oregon.

Recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000.00, with a 5 percent bid discount for certified Small Local Business Enterprises (due March 13, 2026); the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (due April 3, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities, with proposals due March 26, 2026. Activity concentrates in Florida, Texas, and the upper Midwest, with multistate reach through cooperative purchasing mechanisms. The code shows modest recent activity across diverse procurement approaches—emergency-response supplies procurement, health department naloxone programs, and wholesale pharmaceutical contracting—suggesting fragmented but sustained demand across municipal and state health and emergency services.